Stock AnalizLigand Pharmaceuticals Inc. LGND
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Ligand Pharmaceuticals Inc. (LGND) is a healthcare company listed in the US with a market value of about $6.2B. In the twelve months to September 30, 2026 it had revenue of $254M and net income of $51M, a net margin of 20.3%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 119.8, a price to free cash flow of 107.5, 5-year revenue growth of 10% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 70% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254M | $268M | $167M | $131M | $196M | $242M | $164M | — | $251M | $141M | $109M |
| Net income | $51M | $124M | -$4M | $52M | -$33M | $57M | -$3M | $629M | $143M | $13M | -$2M |
| Free cash flow | $57M | $49M | $95M | $46M | $120M | $70M | $50M | -$32M | $193M | $86M | $59M |
| EPS (diluted) | $2.58 | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 | $-0.18 | $31.85 | $5.96 | $0.53 | $-0.08 |
| Net margin | 20.3% | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | -1.8% | — | 57.0% | 8.9% | -1.5% |
| ROIC | — | 2.2% | -2.1% | 1.4% | 0.4% | 7.1% | 2.6% | 45.0% | 11.6% | 8.6% | 6.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $361.27, 17% above the current price; targets range from $335.00 to $406.00; the consensus rating is “Strong buy”; expected EPS is $9.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Ligand Pharmaceuticals’s P/E ratio?
About 119.8, based on the last twelve months of diluted earnings per share (forward P/E about 27.5).
Is Ligand Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 70% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ligand Pharmaceuticals pay a dividend?
Not currently.
Is Ligand Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Ligand Pharmaceuticals scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.